Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma.

@article{Chen2012RecombinantHE,
  title={Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma.},
  author={Xiaofeng Chen and Yiqian Liu and Yongmei Yin and Shidai Jin and Guoqian Ping and O. D. R\oe and Keli Yan and Yongqian Shu and Ren-hua Guo},
  journal={Journal of chemotherapy},
  year={2012},
  volume={24 4},
  pages={
          231-6
        }
}
We report a case of 43-year-old male with advanced malignant mesothelioma (MM) with a large amount of fluid in the pleural and peritoneal cavity. The addition of endostar to the gemcitabine-cisplatin regimen gave a prompt and significant improvement of clinical symptoms and disappearance of ascites. The patient is still progression free after 27 months. Endostar, in combination with chemotherapy should be explored in the treatment of MM, especially its effect on pleural and ascitic fluid. 
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
2 Citations
24 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-2 of 2 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Endostar in mesothelioma

  • Chen
  • Journal of Chemotherapy 2012 VOL. 24 NO
  • 2012

Similar Papers

Loading similar papers…